A 63-Year-Old Man with Myelofibrosis : Episode 5
Pacritinib for Patients With Myelofibrosis
Stephen T. Oh, MD, PhD, discusses patients who would be suitable to receive pacritinib for myelofibrosis, highlighting data showing correlation between transfusion independence and reduction in bone marrow reticulin fibrosis.
Case: A 63-Year-Old Man with Myelofibrosis
Clinical Presentation:
- A 63-year-old man recently diagnosed with primary MF and initiated on 10 mg BID ruxolitinib.
- PMH: type 2 diabetes, hypercholesteremia, and hypertension, squamous cell carcinoma (SCC)
Follow up and Clinical Workup at 3 Months:
- Exam: night sweats improved.
- Labs: Hb 7.8 g/dL; Plt 80 x 109/L (previously 135k) stabilized.
- Some spleen reduction.
- Patient receives ~1 unit RBC per month.
Follow up and Clinical Workup at 6 Months:
- Patient reports complaints of fatigue and abdominal pain.
- Labs: Plt 55 x 109/L; Hgb 6.8 g/dL
- Patient now receives 2 units RBC per month.
- Experienced recurrence of SCC.
Recent Videos
Related Content
